Terns Q1 and Update

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24

Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24

Cash, cash equivalents and marketable securities of $241million, expected to provide runway into 2026

https://www.biospace.com/article/releases/terns-pharmaceuticals-reports-first-quarter-2024-financial-results-and-corporate-updates/